Skip to main content

RGEN

Stock
Health Care
Medical Instruments & Supplies

Performance overview

RGEN Price
Price Chart

Forward-looking statistics

Beta
0.62
Risk
51.33%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.

Company info

SectorHealth Care
IndustryMedical Instruments & Supplies
Employees1K
Market cap$8.1B

Fundamentals

Enterprise value$7.0B
Revenue$650.4M
Revenue per employee
Profit margin-3.53%
Debt to equity34.44

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.42
Dividend per share
Revenue per share$11.61
Avg trading volume (30 day)$95M
Avg trading volume (10 day)$90M
Put-call ratio

Macro factor sensitivity

Growth-0.2
Credit+4.5
Liquidity+1.0
Inflation-4.7
Commodities+0.7
Interest Rates-2.3

Valuation

Dividend yield0.00%
PEG Ratio71.61
Price to sales11.01
P/E Ratio71.61
Enterprise Value to Revenue10.72
Price to book3.61

Upcoming events

Next earnings dayApril 29, 2025
Next dividend day
Ex. dividend day

News

Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report?

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research (May 29, 2025)
908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth

On Tuesday, Repligen Corporation RGEN purchased 908 Devices Inc.'s MASS desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications.

Benzinga (March 4, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free